CA3141534A1 - Nanoparticles comprising enzalutamide - Google Patents

Nanoparticles comprising enzalutamide Download PDF

Info

Publication number
CA3141534A1
CA3141534A1 CA3141534A CA3141534A CA3141534A1 CA 3141534 A1 CA3141534 A1 CA 3141534A1 CA 3141534 A CA3141534 A CA 3141534A CA 3141534 A CA3141534 A CA 3141534A CA 3141534 A1 CA3141534 A1 CA 3141534A1
Authority
CA
Canada
Prior art keywords
nanoparticles
liquid
enzalutamide
polyoxyethylene
nanoparticles according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3141534A
Other languages
English (en)
French (fr)
Inventor
Heiko Brunner
Frank Gindullis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karl O Helm AG
Original Assignee
Karl O Helm AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karl O Helm AG filed Critical Karl O Helm AG
Publication of CA3141534A1 publication Critical patent/CA3141534A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3141534A 2019-05-23 2020-05-22 Nanoparticles comprising enzalutamide Pending CA3141534A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19176304.4 2019-05-23
EP19176304 2019-05-23
EP19209182 2019-11-14
EP19209182.5 2019-11-14
PCT/EP2020/064268 WO2020234448A1 (en) 2019-05-23 2020-05-22 Nanoparticles comprising enzalutamide

Publications (1)

Publication Number Publication Date
CA3141534A1 true CA3141534A1 (en) 2020-11-26

Family

ID=70861458

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3141534A Pending CA3141534A1 (en) 2019-05-23 2020-05-22 Nanoparticles comprising enzalutamide

Country Status (5)

Country Link
US (2) US20220249388A1 (https=)
EP (1) EP3972569A1 (https=)
JP (2) JP2022533463A (https=)
CA (1) CA3141534A1 (https=)
WO (1) WO2020234448A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3915546A1 (de) * 2020-05-25 2021-12-01 Leon-Nanodrugs GmbH Verwendung von säure als lösungsmittel für präzipitationen
WO2024127361A1 (en) * 2022-12-16 2024-06-20 Ferring B.V. Enzalutamide nanocrystals, methods and compositions
EP4651860A1 (en) 2023-01-18 2025-11-26 HELM Pharmaceuticals GmbH Crystalline nanoparticles comprising enzalutamide

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
TW486370B (en) 1996-12-25 2002-05-11 Yamanouchi Pharma Co Ltd Rapidly disintegrable pharmaceutical composition
ATE364374T1 (de) 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
CA2335472C (en) 1998-06-19 2008-10-28 Rtp Pharma Inc. Processes to generate submicron particles of water-insoluble compounds
AU4910300A (en) 1999-04-08 2000-11-14 Bernd Penth Method and device for carrying out chemical and physical processes
CA2436418A1 (en) 2001-01-30 2002-08-08 Board Of Regents, The University Of Texas Systems Process for production of nanoparticles and microparticles by spray freezing into liquid
CA2435721A1 (en) 2001-01-31 2002-08-08 Kraft Foods Holdings, Inc. Production of capsules and particles for improvement of food products
ES2257968B1 (es) 2005-01-28 2007-07-01 Universidad De Sevilla Procedimiento y dispositivo para la obtencion de particulas de tamaño micro y nanometrico.
DE102005017777A1 (de) 2005-04-13 2006-10-19 Pharmasol Gmbh Verfahren zur schonenden Herstellung von hochfeinen Partikelsuspensionen
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
DE102005053862A1 (de) 2005-11-04 2007-05-10 Pharmasol Gmbh Verfahren und Vorrichtung zur Herstellung hochfeiner Partikel sowie zur Beschichtung solcher Partikel
DE102009008478A1 (de) 2009-02-11 2010-08-19 PHAST Gesellschaft für pharmazeutische Qualitätsstandards mbH Vorrichtung und Verfahren zur Herstellung pharmazeutisch hochfeiner Partikel sowie zur Beschichtung solcher Partikel in Mikroreaktoren
EP2550092B1 (de) 2010-03-22 2018-08-15 Instillo GmbH Verfahren zur herstellung von mikro- oder nanopartikeln
WO2014043208A1 (en) 2012-09-11 2014-03-20 Medivation Prostate Therapeutics, Inc. Formulations of enzalutamide
US9901893B2 (en) 2013-03-28 2018-02-27 Instillo Gmbh Apparatus and method for producing dispersions and solids
CA2940984A1 (en) * 2014-02-05 2015-08-13 Lek Pharmaceuticals D.D. Solid pharmaceutical compositions of androgen receptor antagonists
DE102016101232A1 (de) 2016-01-25 2017-07-27 Instillo Gmbh Verfahren zum Herstellen von Emulsionen
WO2019155416A2 (en) * 2018-02-09 2019-08-15 Kashiv Pharma Llc A stable pharmaceutical composition of poorly soluble nonsteroidal antiandrogens

Also Published As

Publication number Publication date
EP3972569A1 (en) 2022-03-30
JP2022533463A (ja) 2022-07-22
JP2025118693A (ja) 2025-08-13
WO2020234448A1 (en) 2020-11-26
US20250262166A1 (en) 2025-08-21
US20220249388A1 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
US12447128B2 (en) Formulations of enzalutamide
US20250262166A1 (en) Nanoparticles comprising enzalutamide
US7923026B2 (en) Embedded micellar nanoparticles
Li et al. The studies of PLGA nanoparticles loading atorvastatin calcium for oral administration in vitro and in vivo
EP2948141A1 (en) Pharmaceutical composition with improved bioavailability
KR20090077074A (ko) 화학 물질의 미셀 나노입자
WO2015152433A1 (en) Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
WO2019155416A2 (en) A stable pharmaceutical composition of poorly soluble nonsteroidal antiandrogens
RS62422B1 (sr) Farmaceutske kompozicije koje sadrže derivat fenilaminopirimidina
Nguyen et al. Preparation of an oil suspension containing ondansetron hydrochloride as a sustained release parenteral formulation
CN113101270A (zh) 一种巴洛沙韦酯组合物及其制备方法
US12178808B2 (en) Amorphous solid dispersion comprising 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide
WO2019240698A2 (en) Oral pharmaceutical composition comprising posaconazole
WO2014203210A1 (en) Nanoparticulate formulation comprising a trpa1 antagonist
TWI392507B (zh) 包埋的膠束奈米顆粒
JP2010521494A (ja) 麻薬性および非麻薬性鎮痛剤の組み合わせ
JPWO2020234448A5 (https=)
US20220354791A1 (en) Mesoporous polymeric particulate material
KR101799539B1 (ko) 도세탁셀을 포함하는 경구용 고형지질나노입자 조성물
HK1138510A (en) Micellar nanoparticles of chemical substances

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240514

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20250505

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250505

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250514

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250514

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250614

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250717

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251113

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260115

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260115

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260115